Clinical tumour sequencing for precision oncology: time for a universal strategy (original) (raw)

Nature Reviews Cancer volume 18, pages 527–528 (2018)Cite this article

Subjects

Routine, comprehensive molecular characterization of patient tumours has the potential to accelerate therapeutic advances and inform cancer biology. Here, we describe insights from the implementation of an enterprise-wide, prospective clinical sequencing strategy at an academic cancer centre.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

$29.99 / 30 days

cancel any time

Subscribe to this journal

Receive 12 print issues and online access

$209.00 per year

only $17.42 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

References

  1. Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 23, 703–713 (2017).
    Article PubMed PubMed Central CAS Google Scholar
  2. Jordan, E. J. et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov. 7, 596–609 (2017).
    Article PubMed PubMed Central CAS Google Scholar
  3. Mandelker, D. et al. Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA versus guideline-based germline testing. JAMA 318, 825–835 (2017).
    Article PubMed PubMed Central Google Scholar
  4. Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409–413 (2017).
    Article PubMed PubMed Central CAS Google Scholar
  5. Drilon, A. et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N. Engl. J. Med. 378, 731–739 (2018).
    Article PubMed PubMed Central CAS Google Scholar
  6. Hyman, D. M. et al. AKT inhibition in solid tumors with AKT1 mutations. J. Clin. Oncol. 35, 2251–2259 (2017).
    Article PubMed PubMed Central Google Scholar
  7. Hyman, D. M. et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554, 189–194 (2018).
    Article PubMed PubMed Central CAS Google Scholar
  8. Coombs, C. C. et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell 21, 374–382 (2017).
    Article PubMed CAS PubMed Central Google Scholar

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Michael L. Cheng, David M. Hyman & David B. Solit
  2. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Michael F. Berger
  3. Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Michael F. Berger & David B. Solit

Authors

  1. Michael L. Cheng
    You can also search for this author inPubMed Google Scholar
  2. Michael F. Berger
    You can also search for this author inPubMed Google Scholar
  3. David M. Hyman
    You can also search for this author inPubMed Google Scholar
  4. David B. Solit
    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toDavid B. Solit.

Ethics declarations

Competing interests

D.B.S. has served in a consulting or advisory role to Loxo Oncology and Pfizer. D.M.H. has served in a consulting or advisory role to Atara Biotherapeutics, Chugai Pharma, CytomX Therapeutics, Boehringer Ingelheim, AstraZeneca, Pfizer and Genentech, and received research funding from AstraZeneca, Puma Biotechnology and Loxo Oncology. M.L.C. and M.F.B. declare no competing interests.

Rights and permissions

About this article

Cite this article

Cheng, M.L., Berger, M.F., Hyman, D.M. et al. Clinical tumour sequencing for precision oncology: time for a universal strategy.Nat Rev Cancer 18, 527–528 (2018). https://doi.org/10.1038/s41568-018-0043-2

Download citation

This article is cited by